Biocon's scrip went down by 3.16 per cent to settle at Rs 412.70 on the BSE. During the day, it lost 3.55 per cent to Rs 411.
On the NSE, it fell by 2.89 per cent to end at Rs 413.05.
Biocon had late last evening reported a 13 per cent dip in net profit for October-December quarter at Rs 91 crore and said it will sell 10-15 per cent stake in its research services arm Syngene.
Revenues stood at Rs 779 crore, up 8 per cent over the corresponding quarter last fiscal.
While approving listing of Syngene through offer for sale route, Biocon Board has also gave approval to initiate the process of appointing merchant bankers. The company would offload 10-15 per cent stake from present holding of 85.54 per cent.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
